Transpek Q1 Results: Net profit falls 43% YoY to ₹8.9 crore
Transpek Industry Limited posted Q1FY27 PAT of ₹8.9 crore, down 42.7% YoY, amid rising raw material and freight costs. Revenue fell 6.5% to ₹155.1 crore. The company is expanding into new chemistries and exploring a new site in Odisha to drive future growth.

*this image is generated using AI for illustrative purposes only.
Transpek Industry Limited reported a significant contraction in profitability for the first quarter of FY27, with net profit after tax (PAT) falling 42.7% year-on-year to ₹8.9 crore. The decline was primarily attributed to a dynamic business environment marked by sharp increases in key raw material costs, specifically sulphur and chlorine, as well as temporary logistical challenges including elevated freight costs and constrained vessel availability.
Total revenue from operations for the quarter stood at ₹155.1 crore, representing a 6.5% decrease compared to ₹165.9 crore in Q1FY26. Despite the revenue dip, the company noted a sequential improvement, with revenue rising 1.7% quarter-on-quarter from ₹152.5 crore in Q4FY26. EBITDA, which includes other income such as export incentives, declined 32.4% YoY to ₹24.1 crore, resulting in an EBITDA margin of 15.6%, down from 21.5% in the corresponding period last year.
Financial Performance Snapshot
| Metric | Q1FY27 | Q1FY26 | YoY Change |
|---|---|---|---|
| Revenue from Operations | ₹151.1 crore | ₹154.2 crore | -2.0% |
| Total Revenue (incl. Other Income) | ₹155.1 crore | ₹165.9 crore | -6.5% |
| EBITDA (incl. Other Income) | ₹24.1 crore | ₹35.7 crore | -32.4% |
| EBITDA Margin | 15.6% | 21.5% | -590 bps |
| Profit After Tax (PAT) | ₹8.9 crore | ₹15.6 crore | -42.7% |
| PAT Margin | 5.8% | 9.4% | -360 bps |
The company’s cost structure faced pressure, with material costs consuming a larger share of revenue. While total raw material costs decreased slightly to ₹72.6 crore from ₹76.7 crore in Q1FY26, this was partly due to inventory changes rather than pure input price moderation. Employee expenses remained stable at ₹18.4 crore, while other expenses rose to ₹39.8 crore from ₹35.2 crore in the prior year period.
What the Numbers Show
A critical divergence exists between the company’s operational revenue and its total reported revenue due to the significant contribution of other income. In Q1FY27, other income stood at ₹4.0 crore, down sharply from ₹11.7 crore in Q1FY26. The presentation notes that a major part of Transpek’s other income consists of export incentives and duty drawbacks directly linked to export sales. With international sales constituting 84.4% of total revenue, fluctuations in these government-linked incentives have a disproportionate impact on the bottom line. The drop in other income was a primary driver behind the wider compression in PAT margins compared to EBITDA margins.
Strategic Outlook and Expansion
Despite near-term headwinds, Transpek Industry is focusing on long-term growth through product diversification and geographic expansion. The company is actively developing non-acid and non-alkyl chloride chemistries, including two polymers, a textile and polymer modifier, and coatings and adhesives additives. Several products are expected to be commercialized in the 2026-2027 timeframe.
Geographically, the company has begun engaging customers in Eurasia and South America, adding to its existing strong presence in North America, which accounted for 52.0% of sales in Q1FY27. Additionally, Transpek is exploring options for a new manufacturing site, having recently received approval from the Odisha Government for land acquisition interest. The company remains cautiously optimistic about future prospects, citing ongoing macroeconomic uncertainties, particularly regarding conflicts in West Asia, as potential risks to global demand and supply conditions.
Historical Stock Returns for Transpek Industry
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.00% | -0.50% | +15.08% | +4.63% | +4.63% | +4.63% |
How might the commercialization of new non-acid and non-alkyl chloride chemistries in 2026-2027 alter Transpek's current reliance on export incentives for profitability?
What is the projected timeline and capital expenditure required for the new manufacturing site in Odisha, and how will it impact future capacity utilization?
Given the 590 bps compression in EBITDA margins, what specific hedging strategies or supply chain adjustments is Transpek implementing to mitigate volatility in sulphur and chlorine prices?


































